Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities (PDMRs), and connected persons, rather than a financial results report.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed is the share price of 1370.24 pence per Ordinary share on July 9, 2015, at which time specific share acquisitions occurred.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details minor share acquisitions by insiders resulting from the re-investment of dividends within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Date: July 9, 2015.
- Share Price: 1370.24 pence per Ordinary share.
- Transaction Type: Acquisitions via dividend re-investment within ISAs.
- Directors/PDMRs Involved: Sir Andrew Witty (118 shares), Mr D S Redfern (22 shares), Mrs V A Whyte (19 shares).
- Connected Persons Involved: Lady C Witty (23 shares).
- Financial Data: No financial performance metrics are included in this specific filing.